Type 2 diabetes mellitus Clinical Trials in the EU, 2026
The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.
About this register
This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,637 trial records at the last sync on 16 Oct 2026, 03:17 UTC; this register shows the 2,557 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.
This page shows the 9 of those trials with a site in Type 2 diabetes mellitus.
How many recently authorised EU trials have a site in Type 2 diabetes mellitus?
9 of the 2,557 most recently authorised trials in this register list a site in Type 2 diabetes mellitus; 5 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.
Summary by phase
| Phase | Trials | Share |
|---|---|---|
| Phase III | 5 | 55.6% |
| Phase I | 2 | 22.2% |
| Phase I/II | 1 | 11.1% |
| Phase II | 1 | 11.1% |
Most active sponsors
| Lead sponsor | Trials |
|---|---|
| AstraZeneca AB | 5 |
| Alnylam Pharmaceuticals Inc. | 1 |
| Corxel Pharmaceuticals Inc. | 1 |
| Jiangsu Hengrui Pharmaceuticals Co. Ltd. | 1 |
| Tecnimede-Sociedade Tecnico-Medicinal S.A. | 1 |